MI PROFILE™

Final Report

CARIS LIFE SCIENCES

Patient

Name: Patient, Test
Date of Birth: XX/Mon/19XX
Sex: Female
Case Number: TN19-XXXXXX
Diagnosis: Endometrioid adeno-carcinoma, NOS

Specimen Information

Primary Tumor Site: Endometrium
Specimen Site: Uterus, NOS
Specimen ID: ABC-1234-XYZ
Specimen Collected: XX-Mon-2019
Completion of Testing: XX-Mon-2019

Ordered By

Ordering Physician, MD
Cancer Center
123 Main Street
Springfield, XY 12345,
USA
1 (123) 456-7890

High Impact Results

BIOMARKER	METHOD	RESULT	THERAPY ASSOCIATION		BIOMARKER LEVEL*
Mismatch Repair Status	**IHC**	**Deficient**	**BENEFIT**	**pembrolizumab**	**Level 1**
MSI	**NGS**	**High**			
ER	IHC	Positive | 2+, 95%	BENEFIT	endocrine therapy	Level 3B
PR	IHC	Positive | 2+, 95%			

* Biomarker reporting classification: Level 1 - highest level of clinical evidence and/or biomarker association included on the drug label; Level 2 - strong evidence of clinical significance and is endorsed by standard clinical guidelines; Level 3 - potential clinical significance (3A - evidence exists in patient's tumor type, 3B - evidence exists in another tumor type).

Important Note

This patient has a potential NCI-MATCH Trial-eligible result. Please see Clinical Trial *see page 6*

Additional Results

CANCER TYPE RELEVANT BIOMARKERS

Biomarker	Method	Result
Tumor Mutational Burden		Intermediate | 9 Mutations/Mb
POLE	NGS	Mutation Not Detected

OTHER FINDINGS (see page 2 for additional results)

Biomarker	Method	Result
PD-L1	SP142 IHC	Negative | 0
ARID1A	NGS	Mutated, Pathogenic
		Exon 12 | p.G1110*
	NGS	Mutated, Pathogenic
		Exon 20 | p.F2141fs
CTNNB1	NGS	Mutated, Pathogenic
		Exon 3 | p.S45del

OTHER FINDINGS (cont) (see page 2 for additional results)

Biomarker	Method	Result
JAK1	NGS	Mutated, Pathogenic
		Exon 19 | p.K860fs
NBN	NGS	Mutated, Pathogenic
		Exon 10 | p.R466fs
PIK3R1	NGS	Mutated, Presumed Pathogenic
		Exon 13 | p.T576del
PTEN	NGS	Mutated, Pathogenic
		Exon 9 | p.Y346fs
	IHC	Positive | 1+, 10%
SETD2	NGS	Mutated, Pathogenic
		Exon 3 | p.R1407fs

Biomarker Results

This summary includes biomarkers most commonly associated with cancer. Complete details of all biomarkers tested can be found in the Appendix.

GENOMIC SIGNATURES		
Biomarker	**Method**	**Result**
Microsatellite Instability (MSI)	NGS	High
Tumor Mutational Burden (TMB)	NGS	

GENES TESTED WITH MUTATIONS/ALTERATIONS						
Gene	**Method**	**Variant Interpretation**	**Protein Alteration**	**Exon**	**DNA Alteration**	**Variant Frequency %**
ARID1A	NGS	Mutated, Pathogenic	p.G1110*	12	c.3328G>T	32
	NGS	Mutated, Pathogenic	p.F2141fs	20	c.6420delC	39
BRCA2	NGS	Mutated, Variant of Unknown Significance	p.C19Y	2	c.56G>A	40
CTNNB1	NGS	Mutated, Pathogenic	p.S45del	3	c.133 _135delTCT	11
JAK1	NGS	Mutated, Pathogenic	p.K860fs	19	c.2580delA	7
NBN	NGS	Mutated, Pathogenic	p.R466fs	10	c.1396dupA	33
PIK3R1	NGS	Mutated, Presumed Pathogenic	p.T576del	13	c.1727 _1729delCGA	33
PTEN	NGS	Mutated, Variant of Unknown Significance	p.T277R	8	c.830C>G	38
	NGS	Mutated, Pathogenic	p.Y346fs	9	c.1038 _1053del16	37
SETD2	NGS	Mutated, Pathogenic	p.R1407fs	3	c.4219delA	7

Unclassified alterations for DNA sequencing can be found in the Appendix.
Formal nucleotide nomenclature and gene reference sequences can be found in the appendix of this report.

Transcript ID and Variants of Unknown Significance can be found in the Appendix.

4610 South 44th Place, Suite 100 • Phoenix, AZ 85040 • (888) 979-8669 • Fax: (866) 479-4925
CLIA 03D1019490 • CAP 7195577 • ISO 15189:2012 • Zoran Gatalica, MD, DSc, Medical Director •

Clinical Trials Connector™

For a complete list of open, enrolling clinical trials visit MI Portal to access the **Clinical Trials Connector**. This personalized, real-time web-based service provides additional clinical trial information and enhanced searching capabilities, including, but not limited to:

- Location: filter by geographic area
- Biomarker(s): identify specific biomarkers associated with open clinical trials to choose from
- Drug(s): search for specific therapies
- Trial Sponsor: locate trials based on the organization supporting the trial(s)

Visit www.CarisMolecularIntelligence.com to view all matched trials. Therapeutic agents listed below may or may not be currently FDA approved for the tumor type tested.

NCI MATCH BIOMARKER SUMMARY			
Description	**Biomarker**	**Method**	**Investigational Agent(s)**
PTEN mutation / copanlisib	PTEN	NGS	copanlisib

Please note that all NCI MATCH arms associated with this case may not be actively recruiting for enrollment, please contact NCI for confirmation.

Please note regarding amplification inclusion criteria: NCI MATCH gene amplification (CNA) thresholds are higher than the Caris reporting thresholds. As a result, only genes with amplification levels above the NCI MATCH threshold are shown in the table above.

CHEMOTHERAPY CLINICAL TRIALS (14)			
Drug Class	**Biomarker**	**Method**	**Investigational Agent(s)**
Anti-hormonal therapy (14)	ER	IHC	anastrozole, exemestane, fulvestrant, letrozole
	PR	IHC	

TARGETED THERAPY CLINICAL TRIALS (229)			
Drug Class	**Biomarker**	**Method**	**Investigational Agent(s)**
Akt inhibitors (5)	ARID1A	NGS	ARQ092, AZD5363
Immunomodulatory agents (154)	Mismatch Repair Status	IHC	MEDI4736, MK-3475, MPDL3280A, MSB0010718C, atezolizumab, avelumab, durvalumab, nivolumab, pembrolizumab
	MLH1	IHC	
	MSI	NGS	
	PMS2	IHC	
MDM2 inhibitors (3)	TP53	NGS	ALRN-6924, DS-3032, RO5503781
PARP inhibitors (40)	MLH1	IHC	BMN-673, MK4827, niraparib, olaparib, rucaparib, talazoparib, veliparib
	PMS2	IHC	
	PTEN	NGS	

( ) = represents the total number of clinical trials identified by the Clinical Trials Connector for the provided drug class or table.

Please refer to the "Notes of Significance" section that may contain additional information regarding therapy associations.

Additional Clinical Trials Connector results continued on the next page. >

4610 South 44th Place, Suite 100 • Phoenix, AZ 85040 • (888) 979-8669 • Fax: (866) 479-4925

To view the rest of the report, contact a Caris Molecular Intelligence® representative today.

(888) 979- 8669
CustomerSupport@carisls.com

4610 South 44th Place, Suite 100 • Phoenix, AZ 85040 • (888) 979-8669 • Fax: (866) 479-4925